Author: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, 2002. Updated by Dr Jannet Gomez, October 2016.

What is measles?

Measles is a highly contagious viral infection causing fever and a rash. Early symptoms are like the common cold, with conjunctivitis (sore red eyes) and cough. Small white spots called Koplik spots may be seen in the mouth. A red blotchy rash appears on the face on the third day of the illness, spreads to the trunk, and becomes more generalised over the next few days.

Measles is also known as English measles, rubeola and morbilli. It is a notifiable disease.

What is the cause of measles?

Measles is caused by measles virus, which belongs to the morbillivirus family.

How common is measles?

Before widespread immunisation against measles in industrialised countries, measles was a very common childhood disease that carried a high death rate. Nowadays in countries where measles is part of an immunisation programme, the risk of exposure and incidence of actual disease cases is low. A recent trend by some parents not to immunise their children has led to an increase in the number of cases of measles, and its complications.

In developing countries, measles still occurs frequently and is associated with a high rate of complications and death. It remains a common disease even in some developed countries of Europe and Asia. Measles still causes more than a million childhood deaths each year.

How do you get measles?

Measles is highly contagious and is easily spread from person to person by breathing in airborne respiratory droplets from an infected person's coughing or sneezing.

An infected person is contagious from 2 days before any symptoms show to at least 5 days after the onset of rash.

An acute infection of measles almost always gives lifelong immunity.

Who is at risk of measles?

Groups of individuals who are at greater risk of measles infection include:

  • Infants who have lost their passive immunity from their mothers (acquired from their mother through transfer of antibody across the placenta) and before their first immunisation
  • Unvaccinated travellers to areas where measles is endemic
  • Individuals with immunodeficiency (eg due to infection with HIV/AIDS, leukaemia, cancer, corticosteroid therapy), regardless of their immunisation status
  • Migrants and refugees

Individuals at greater risk for severe measles and its complications include:

  • Malnourished individuals (particularly children that are deficient in vitamin A)
  • Those with an underlying immune deficiency
  • Pregnant women

What are the signs and symptoms of measles?


See more images of measles ...

Measles appears as distinct clinical stages.

Incubation period

  • Ranges from 7–14 days (average 10–11 days).
  • Patient usually have no symptoms.
  • Some may experience symptoms of primary viral spread (fever, spotty rash and respiratory symptoms due to virus in the blood stream) within 2–3 days of exposure.


  • Generally occurs around 10–12 days from exposure.
  • Appears as fever, malaise and loss of appetite, followed by conjunctivitis (red eyes), cough and coryza (blocked or runny nose).
  • 2–3 days into the prodromal phase, Koplik spots appear. These are blue-white spots on the inside of the mouth opposite the molars, and occur 24–48 hours before the exanthem (rash) stage.
  • Symptoms usually last for 2–5 days but in some cases may persist for as long as 7–10 days.

Exanthem (rash)

  • Red spots ranging from 0.1–1.0cm in diameter appear on the 4th or 5th day following the start of symptoms.
  • This non-itchy rash begins on face and behind the ears. Within 24–36 hours it spreads to the entire trunk and extremities (palms and soles rarely involved).
  • The spots may all join together, especially in areas of the face.
  • Rash usually coincides with the appearance of a high fever >/= 40C.
  • Rash begins to fade 3–4 days after it first appears. To begin with it fades to a purplish hue and then to brown/coppery coloured lesions with fine scales.


  • Cough may persist for 1–3 weeks.
  • Measles-associated complications may be the cause of persisting fever beyond the 3rd day of the rash

How is measles diagnosed?

Diagnosis of measles is based on the characteristic history and physical examination. Because the disease is now so rarely seen in developed countries, any suspected cases require laboratory confirmation. This is particularly useful in the following situations:

  • Sporadic cases
  • Atypical cases
  • Confusion with other diseases

The usual way to diagnose acute measles is using a viral nasopharyngeal swab and throat swab for polymerase chain reaction (PCR). Blood and urine samples can also be used. This should be done within 5 days of onset of rash, however, positive results are sometimes obtained up to 10–14 days after the rash has resolved.

Blood is also taken for measles IgM and IgG antibodies (serology). Levels of IgM become elevated during the active infection phase and IgG antibody appears during the recovery phase.

Viral culture of throat and nasopharyngeal swabs is preferred in immunocompromised patients where serological evidence might be absent due to decreased immune response. An immunofluorescence test for measles antigen can also be considered in patients with poor immunity.

What is the treatment of measles?

There is no specific treatment for measles, which is why immunisation is so important. Treatment for mild cases of measles is supportive. Bed rest is vital, as it prevents complications and prevents  spread of the virus.

  • Give paracetamol for fever. Aspirin should not be given to a child with viral illness, as it is associated with the development of Reyes syndrome.
  • Vitamin A for children in developing countries or that are malnourished.  WHO recommends  dose of 200,000 international units (IU) of vitamin A for two days, for reducing measles and its complications.
  • Maintain adequate fluid intake to prevent dehydration  
  • Use a humidifier to provide relief from cough/sore throat
  • Provide nutritional support as necessary
  • Observe high-risk individuals carefully to prevent complications

Patients with drowsiness, dehydration, or discomfort breathing require hospitalisation for supportive care. 

Antibiotics are needed to treat secondary bacterial infections from complications such as otitis media, infectious diarrhoea, pneumonia and sepsis. Ribavirin (antiviral) is used to treat measles infection in immunocompromised patients and in those affected with subacute sclerosing panencephalitis.

What are the complications from measles?

Approximately 30% of reported measles cases have one or more complications. 

  • Gastrointestinal: diarrhoea that may be fatal if dehydration occurs, mouth ulceration,  appendicitis, hepatitis, mesenteric adenitis and pancreatitis
  • Ears: otitis media (almost exclusively in children), which may lead to deafness
  • Respiratory tract: laryngobronchitis, measles croup, and pneumonia (either primary viral or secondary bacterial) — the most common cause of death from measles
  • Heart: myocarditis and pericarditis
  • Haematological system: thrombocytopenia, causing bleeding and disseminated intravascular coagulation (DIC)
  • Eyes: conjunctivitis and/or corneal ulceration leading to blindness (especially if vitamin A deficient), and squint
  • Kidneys: acute glomerulonephritis (inflammation of kidneys) and renal failure
  • Nervous system: febrile seizures and encephalitis
  • Malnutrition (especially if from poor community)
  • Measles infection during pregnancy increases the risk of premature labour and delivery, fetal loss and maternal death

Rarely, subacute sclerosing panencephalitis—a fatal condition—develops decades after measles infection due to persistence of the measles virus in the central nervous system.

How can measles be prevented?

Measles can be prevented by vaccination with live attenuated measles vaccine. It is available as a single antigen preparation or combined with live attenuated mumps or rubella vaccines, or both. Combined measles, mumps and rubella (MMR) vaccine is currently part of routine immunisation programmes in most industrialised countries, including New Zealand.

Measles vaccine induces long-term (probably life-long) immunity in most individuals. Vaccination schedules recommend a two-dose immunisation strategy, the first dose at 12–15 months, followed by a second dose at 4–6 years.

Measles vaccine should not be given during pregnancy. Women not previously immunised against measles should avoid pregnancy for one month (28 days) after receiving the MMR vaccine.

Immune globulin does not prevent measles, but it is helpful in decreasing the severity of illness in those exposed to the virus. It is recommended for:

  • Pregnant women 
  • People with immune deficiency
  • Infants 

Individuals vaccinated prior to 1968 may require revaccination, as vaccines used before this time may not have conferred life-long immunity.


Related Information


On DermNet NZ

Other websites

  • Measles – translation of DermNet NZ page into Ukrainian language, 3 September 2015 by Viktoriya Parnak
  • Корь – translation of DermNet NZ page into Russian language, 3 September 2015 by Viktoriya Parnak
  • Адзер – translation of DermNet NZ page into Belarussian language, 03 April 2016 by Valerie Bastiaan
  • Masalas – translation of DermNet NZ page into Latvian language, 08 February 2017 by Arija Liepkalnietis
  • Odra — translation of DermNet NZ page into Polish language, 11 May 2017 by Marie Stefanova
  • Measles– Medline Plus
  • Measles — Immunisation Handbook 2017, Ministry of Health, NZ
  • Measles – Immunisation Advisory Centre, University of Auckland
  • Measles World Health Organization (WHO)
  • Measles, rubeola – Medscape Reference
  • Measles – emedicinehealth
  • Measles – NHS Choices